Credit Suisse Group set a GBX 6,350 ($82.97) price objective on AstraZeneca (LON:AZN) in a research note published on Friday, March 29th, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
AZN has been the subject of a number of other reports. Barclays reissued an overweight rating on shares of AstraZeneca in a research report on Tuesday, February 5th. Deutsche Bank reissued a buy rating and issued a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research report on Tuesday, March 5th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research note on Monday, February 25th. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) price target on AstraZeneca and gave the stock a buy rating in a report on Tuesday, January 29th. Finally, Goldman Sachs Group set a GBX 4,080 ($53.31) price target on AstraZeneca and gave the stock a sell rating in a report on Thursday, February 14th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of GBX 6,362.70 ($83.14).
Shares of LON AZN traded down GBX 99 ($1.29) during trading hours on Friday, reaching GBX 5,815 ($75.98). The stock had a trading volume of 2,258,433 shares, compared to its average volume of 2,310,000. The stock has a market cap of $76.28 billion and a PE ratio of 34.21. The company has a quick ratio of 0.71, a current ratio of 0.96 and a debt-to-equity ratio of 136.31. AstraZeneca has a fifty-two week low of GBX 4,928.50 ($64.40) and a fifty-two week high of GBX 6,540 ($85.46).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.